Immune precision

Third Rock Ventures is taking a page from cancer and Orphan diseases by launching Rheos Medicines Inc. to identify novel biomarkers and targets that will enable patient stratification and the development of precision medicines for autoimmune and inflammatory diseases. The VC provided Rheos with a $60 million series A round to further build out the platform and bring its first candidate into the clinic.

Interim CEO and Third Rock partner Abbie Celniker told BioCentury that current autoimmune and inflammatory disease therapies are “one-size fits all,” and not “customized to specific cells driving a specific disease.”...